

Miguel Casas

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11483505/publications.pdf>

Version: 2024-02-01

123
papers

7,826
citations

76326

40
h-index

58581

82
g-index

133
all docs

133
docs citations

133
times ranked

12203
citing authors

#	ARTICLE	IF	CITATIONS
1	Dissecting the Shared Genetic Architecture of Suicide Attempt, Psychiatric Disorders, and Known Risk Factors. <i>Biological Psychiatry</i> , 2022, 91, 313-327.	1.3	114
2	Attention-deficit/hyperactivity disorder and lifetime cannabis use: genetic overlap and causality. <i>Molecular Psychiatry</i> , 2020, 25, 2493-2503.	7.9	59
3	International Consensus Statement for the Screening, Diagnosis, and Treatment of Adolescents with Concurrent Attention-Deficit/Hyperactivity Disorder and Substance Use Disorder. <i>European Addiction Research</i> , 2020, 26, 223-232.	2.4	28
4	Transcriptome profiling in adult attention-deficit hyperactivity disorder. <i>European Neuropsychopharmacology</i> , 2020, 41, 160-166.	0.7	7
5	Validity of the ADHD module of the Mini International Neuropsychiatric Interview PLUS for screening of adult ADHD in treatment seeking substance use disorder patients: ADHD screening with MINI-Plus. <i>Revista De Psiquiatria Y Salud Mental</i> , 2020, , .	1.8	6
6	Professional perception of clozapine use in patients with dual psychosis. <i>Actas Espanolas De Psiquiatria</i> , 2020, 48, 99-105.	0.1	2
7	ADGRL3 (LPHN3) variants predict substance use disorder. <i>Translational Psychiatry</i> , 2019, 9, 42.	4.8	29
8	Genome-wide analysis of emotional lability in adult attention deficit hyperactivity disorder (ADHD). <i>European Neuropsychopharmacology</i> , 2019, 29, 795-802.	0.7	6
9	Epigenetic signature for attention-deficit/hyperactivity disorder: identification of miR-26b-5p, miR-185-5p, and miR-191-5p as potential biomarkers in peripheral blood mononuclear cells. <i>Neuropsychopharmacology</i> , 2019, 44, 890-897.	5.4	31
10	Integrative genomic analysis of methylphenidate response in attention-deficit/hyperactivity disorder. <i>Scientific Reports</i> , 2018, 8, 1881.	3.3	14
11	Alcohol use disorder and cognitive impairment in old age patients: A 6 months follow-up study in an outpatient unit in Barcelona. <i>Psychiatry Research</i> , 2018, 261, 361-366.	3.3	18
12	A Genetic Investigation of Sex Bias in the Prevalence of Attention-Deficit/Hyperactivity Disorder. <i>Biological Psychiatry</i> , 2018, 83, 1044-1053.	1.3	146
13	Sex differences in an old adult sample with substance use disorder: A 6 months follow-up study. <i>Psychiatry Research</i> , 2018, 270, 1157-1165.	3.3	2
14	Analysis of shared heritability in common disorders of the brain. <i>Science</i> , 2018, 360, .	12.6	1,085
15	Genome-wide association meta-analysis of age at first cannabis use. <i>Addiction</i> , 2018, 113, 2073-2086.	3.3	24
16	Cannabinoids therapeutic use: what is our current understanding following the introduction of THC, THC:CBD oromucosal spray and others?. <i>Expert Review of Clinical Pharmacology</i> , 2017, 10, 443-455.	3.1	66
17	Severity factors associated with borderline personality disorder among misusers in an outpatient sample in Spain. <i>Journal of Addictive Diseases</i> , 2017, 36, 93-96.	1.3	13
18	Dual Disorders: A Clinical Perspective. <i>Addictive Disorders and Their Treatment</i> , 2017, 16, 175-179.	0.5	5

#	ARTICLE	IF	CITATIONS
19	Differences in the association between childhood trauma history and borderline personality disorder or attention deficit/hyperactivity disorder diagnoses in adulthood. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2017, 267, 541-549.	3.2	25
20	Professionals' perception on the management of patients with dual disorders. <i>Patient Preference and Adherence</i> , 2016, Volume 10, 1855-1868.	1.8	21
21	Effectiveness of Inhaled Loxapine in Dual-Diagnosis Patients: A Case Series. <i>Clinical Neuropharmacology</i> , 2016, 39, 206-209.	0.7	14
22	Prevalence and Predictors of Posttraumatic Stress Symptomatology Among Burn Survivors. <i>Journal of Burn Care and Research</i> , 2016, 37, e79-e89.	0.4	76
23	Borderline Personality Disorder and Personality Inventory for DSM-5 (PID-5): Dimensional personality assessment with DSM-5. <i>Comprehensive Psychiatry</i> , 2016, 70, 105-111.	3.1	14
24	Psychiatric comorbidities in opioid-dependent patients undergoing a replacement therapy programme in Spain: The PROTEUS study. <i>Psychiatry Research</i> , 2016, 243, 174-181.	3.3	44
25	The Fenix II study: A longitudinal study of psychopathology among burn patients. <i>Burns</i> , 2016, 42, 1201-1211.	1.9	21
26	Clinical differences between cocaine-dependent patients with and without antisocial personality disorder. <i>Psychiatry Research</i> , 2016, 246, 587-592.	3.3	10
27	Cocaine-induced Psychosis and Brain-derived Neurotrophic Factor in Patients with Cocaine Dependence: Report of Two Cases. <i>Clinical Psychopharmacology and Neuroscience</i> , 2016, 14, 109-113.	2.0	6
28	Relevant Differences in Perception and Knowledge of Professionals in Different Spanish Autonomous Communities Regarding Availability of Resources for Patients with Dual disorders. <i>Actas Espanolas De Psiquiatria</i> , 2016, 44, 1-12.	0.1	0
29	Impulsive clinical profile of Borderline Personality Disorder with comorbid Substance Use Disorder. <i>Actas Espanolas De Psiquiatria</i> , 2016, 44, 145-52.	0.1	6
30	Study of prevalence of Personality Disorders in inmate men sample with Substance Use Disorders using of PDQ-4+ Self-Report. <i>Actas Espanolas De Psiquiatria</i> , 2016, 44, 178-82.	0.1	3
31	Assessing knowledge and attitudes towards addictions in medical residents of a general hospital. <i>Drugs: Education, Prevention and Policy</i> , 2015, 22, 457-462.	1.3	4
32	Dopamine receptor DRD4 gene and stressful life events in persistent attention deficit hyperactivity disorder. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2015, 168, 480-491.	1.7	18
33	New suggestive genetic loci and biological pathways for attention function in adult attention deficit/hyperactivity disorder. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2015, 168, 459-470.	1.7	78
34	Reply to the Letter to the Editor: "Depression symptoms in burn patients". <i>Burns</i> , 2015, 41, 1895-1896.	1.9	0
35	Cortisol Response to Stress in Adults with Attention Deficit Hyperactivity Disorder. <i>International Journal of Neuropsychopharmacology</i> , 2015, 18, pyv027.	2.1	21
36	Changes in brain-derived neurotrophic factor (BDNF) during abstinence could be associated with relapse in cocaine-dependent patients. <i>Psychiatry Research</i> , 2015, 225, 309-314.	3.3	26

#	ARTICLE	IF	CITATIONS
37	Joint Analysis of Psychiatric Disorders Increases Accuracy of Risk Prediction for Schizophrenia, Bipolar Disorder, and Major Depressive Disorder. <i>American Journal of Human Genetics</i> , 2015, 96, 283-294.	6.2	225
38	Criteria and Concurrent Validity of Adult ADHD Section of the Psychiatry Research Interview for Substance and Mental Disorders. <i>Journal of Attention Disorders</i> , 2015, 19, 999-1006.	2.6	17
39	Childhood trauma in Chronic Fatigue Syndrome: focus on personality disorders and psychopathology. <i>Comprehensive Psychiatry</i> , 2015, 62, 13-19.	3.1	6
40	¿El trastorno por déficit de atención con hiperactividad es siempre destructivo?. <i>Revista Espanola De Medicina Legal</i> , 2015, 41, 45-46.	0.1	0
41	Group Therapy for Adolescents With Attention-Deficit/Hyperactivity Disorder: A Randomized Controlled Trial. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2015, 54, 275-282.	0.5	46
42	History of sexual, emotional or physical abuse and psychiatric comorbidity in substance-dependent patients. <i>Psychiatry Research</i> , 2015, 229, 743-749.	3.3	54
43	Adult ADHD Screening in Alcohol-Dependent Patients Using the Wender Utah Rating Scale and the Adult ADHD Self-Report Scale. <i>Journal of Attention Disorders</i> , 2015, 19, 328-334.	2.6	43
44	Case-Control Genome-Wide Association Study of Persistent Attention-Deficit Hyperactivity Disorder Identifies FBXO33 as a Novel Susceptibility Gene for the Disorder. <i>Neuropsychopharmacology</i> , 2015, 40, 915-926.	5.4	59
45	Bipolar Disorders and Co-Occurring Addictions. , 2015, , 1959-1970.		0
46	Comorbid personality disorders in chronic fatigue syndrome patients: a marker of psychopathological severity. <i>Actas Espanolas De Psiquiatria</i> , 2015, 43, 58-65.	0.1	6
47	Neuroticism Associated with Cocaine-Induced Psychosis in Cocaine-Dependent Patients: A Cross-Sectional Observational Study. <i>PLoS ONE</i> , 2014, 9, e106111.	2.5	17
48	Stimulant drugs trigger transient volumetric changes in the human ventral striatum. <i>Brain Structure and Function</i> , 2014, 219, 23-34.	2.3	23
49	Changes in the serum levels of brain-derived neurotrophic factor in adults with attention deficit hyperactivity disorder after treatment with atomoxetine. <i>Psychopharmacology</i> , 2014, 231, 1389-1395.	3.1	17
50	Addressing the lack of studies in attention-deficit/hyperactivity disorder in adults. <i>Expert Review of Neurotherapeutics</i> , 2014, 14, 553-567.	2.8	30
51	Clinical differences between cocaine-induced psychotic disorder and psychotic symptoms in cocaine-dependent patients. <i>Psychiatry Research</i> , 2014, 216, 398-403.	3.3	22
52	Psychiatric comorbidity in treatment-seeking substance use disorder patients with and without attention deficit hyperactivity disorder: results of the IASP study. <i>Addiction</i> , 2014, 109, 262-272.	3.3	129
53	Relationship between poor decision-making process and fatigue perception in Parkinson's disease patients. <i>Journal of the Neurological Sciences</i> , 2014, 337, 167-172.	0.6	20
54	Prevalence of attention deficit/hyperactivity disorder symptoms in outpatient adolescents and young adults with other psychiatric disorders refractory to previous treatments. <i>Revista De Psiquiatria Y Salud Mental (English Edition)</i> , 2014, 7, 104-112.	0.3	3

#	ARTICLE	IF	CITATIONS
55	Dual Diagnosis Resource Needs in Spain: A National Survey of Professionals. <i>Journal of Dual Diagnosis</i> , 2014, 10, 84-90.	1.2	15
56	Professionals'™ perceptions about healthcare resources for co-occurring disorders in Spain. <i>International Journal of Mental Health Systems</i> , 2014, 8, 35.	2.7	5
57	Functioning Assessment Short Test (FAST): validity and reliability in adults with attention-deficit/hyperactivity disorder. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2014, 264, 719-727.	3.2	16
58	Epidemiology of substance abuse among migrants compared to native born population in primary care. <i>American Journal on Addictions</i> , 2014, 23, 337-342.	1.4	11
59	Emotional lability: The discriminative value in the diagnosis of attention deficit/hyperactivity disorder in adults. <i>Comprehensive Psychiatry</i> , 2014, 55, 1712-1719.	3.1	30
60	Variability in the prevalence of adult ADHD in treatment seeking substance use disorder patients: Results from an international multi-center study exploring DSM-IV and DSM-5 criteria. <i>Drug and Alcohol Dependence</i> , 2014, 134, 158-166.	3.2	150
61	Genome-wide copy number variation analysis in adult attention-deficit and hyperactivity disorder. <i>Journal of Psychiatric Research</i> , 2014, 49, 60-67.	3.1	50
62	An independent components and functional connectivity analysis of resting state fMRI data points to neural network dysregulation in adult ADHD. <i>Human Brain Mapping</i> , 2014, 35, 1261-1272.	3.6	147
63	Chapitre 1. Introduction À la notion de comorbidité et concept de dual diagnosis. , 2014, , 1-10.		0
64	Driving and legal status of Spanish opioid-dependent patients. <i>Substance Abuse Treatment, Prevention, and Policy</i> , 2013, 8, 19.	2.2	3
65	Attention deficit hyperactivity disorder in cocaine-dependent adults: A psychiatric comorbidity analysis. <i>American Journal on Addictions</i> , 2013, 22, 466-473.	1.4	42
66	Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs. <i>Nature Genetics</i> , 2013, 45, 984-994.	21.4	2,067
67	Psychotic Symptoms of Cocaine Self-Injectors in a Harm Reduction Program. <i>Substance Abuse</i> , 2013, 34, 118-121.	2.3	12
68	Brain-derived neurotrophic factor serum levels in cocaine-dependent patients during early abstinence. <i>European Neuropsychopharmacology</i> , 2013, 23, 1078-1084.	0.7	49
69	Evaluation of single nucleotide polymorphisms in the miR-183-96-182 cluster in adulthood attention-deficit and hyperactivity disorder (ADHD) and substance use disorders (SUDs). <i>European Neuropsychopharmacology</i> , 2013, 23, 1463-1473.	0.7	38
70	Toward a Better Understanding of Attention-Deficit/Hyperactivity Disorder Across the Lifespan. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2013, 52, 119-120.	0.5	4
71	Validity of the Adult ADHD Self-Report Scale (ASRS) as a screener for adult ADHD in treatment seeking substance use disorder patients. <i>Drug and Alcohol Dependence</i> , 2013, 132, 587-596.	3.2	135
72	Evaluation of common variants in 16 genes involved in the regulation of neurotransmitter release in ADHD. <i>European Neuropsychopharmacology</i> , 2013, 23, 426-435.	0.7	28

#	ARTICLE	IF	CITATIONS
73	Epidemiology of psychiatric morbidity among migrants compared to native born population in Spain: a controlled study. <i>General Hospital Psychiatry</i> , 2013, 35, 93-99.	2.4	22
74	Exploring the clinical validity of borderline personality disorder components. <i>Comprehensive Psychiatry</i> , 2013, 54, 34-40.	3.1	14
75	Cocaine-Induced Psychosis and Impulsivity in Cocaine-Dependent Patients. <i>Journal of Addictive Diseases</i> , 2013, 32, 263-273.	1.3	22
76	Gender Differences in Dually Diagnosed Outpatients. <i>Substance Abuse</i> , 2013, 34, 78-80.	2.3	11
77	Decreased serum levels of brain-derived neurotrophic factor in adults with attention-deficit hyperactivity disorder. <i>International Journal of Neuropsychopharmacology</i> , 2013, 16, 1267-1275.	2.1	56
78	Rethinking Dual Disorders/Pathology. <i>Addictive Disorders and Their Treatment</i> , 2013, 12, 1-10.	0.5	34
79	Serum Brain-Derived Neurotrophic Factor Levels and Cocaine-Induced Transient Psychotic Symptoms. <i>Neuropsychobiology</i> , 2013, 68, 146-155.	1.9	17
80	Efficacy and safety of prolonged-release OROS methylphenidate in adults with attention deficit/hyperactivity disorder: A 13-week, randomized, double-blind, placebo-controlled, fixed-dose study. <i>World Journal of Biological Psychiatry</i> , 2013, 14, 268-281.	2.6	26
81	Perception of Spanish professionals on therapeutic adherence of dual diagnosis patients. <i>Actas Espanolas De Psiquiatria</i> , 2013, 41, 319-29.	0.1	7
82	Laminar Thickness Alterations in the Fronto-Parietal Cortical Mantle of Patients with Attention-Deficit/Hyperactivity Disorder. <i>PLoS ONE</i> , 2012, 7, e48286.	2.5	32
83	Feasibility of Double-Blind Clinical Trials with Oral Diacetylmorphine: A Randomized Controlled Phase II Study in an Inpatient Setting. <i>European Addiction Research</i> , 2012, 18, 279-287.	2.4	7
84	Attention-deficit hyperactivity disorder in chronic fatigue syndrome patients. <i>Psychiatry Research</i> , 2012, 200, 748-753.	3.3	28
85	Validez de criterio y concurrente de la versi3n espaola de la Conners Adult ADHD Diagnostic Interview for DSM-IV. <i>Revista De PsiquiatrAa Y Salud Mental</i> , 2012, 5, 229-235.	1.8	45
86	Criterion and concurrent validity of Conners Adult ADHD Diagnostic Interview for DSM-IV (CAADID) Spanish version. <i>Revista De PsiquiatrAa Y Salud Mental (English Edition)</i> , 2012, 5, 229-235.	0.3	12
87	Response inhibition and reward anticipation in medication-naïve adults with attention-deficit/hyperactivity disorder: A within-subject case-control neuroimaging study. <i>Human Brain Mapping</i> , 2012, 33, 2350-2361.	3.6	78
88	Borderline Personality Disorder (BPD) diagnosis with the self-report Personality Diagnostic Questionnaire-4+(PDQ-4+): confirmation of the 3-factor structure. <i>Actas Espanolas De Psiquiatria</i> , 2012, 40, 57-62.	0.1	3
89	Treatment adherence to treatment in substance users referred from Psychiatric Emergency service to outpatient treatment. <i>Actas Espanolas De Psiquiatria</i> , 2012, 40, 63-9.	0.1	7
90	Prevalence and risk factors of psychotic symptoms in cocaine-dependent patients. <i>Actas Espanolas De Psiquiatria</i> , 2012, 40, 187-97.	0.1	27

#	ARTICLE	IF	CITATIONS
91	The SCID-II and DIB-R interviews: diagnostic association with poor outcome risk factors in Borderline Personality Disorder. <i>Psicothema</i> , 2012, 24, 523-8.	0.9	2
92	Achieving Remission as a Routine Goal of Pharmacotherapy in Attention-Deficit Hyperactivity Disorder. <i>CNS Drugs</i> , 2011, 25, 17-36.	5.9	25
93	Efficacy of Methylphenidate for Adults with Attention-Deficit Hyperactivity Disorder. <i>CNS Drugs</i> , 2011, 25, 157-169.	5.9	192
94	Efficacy of indirect dopamine agonists for psychostimulant dependence: A systematic review and meta-analysis of randomized controlled trials. <i>Journal of Substance Abuse Treatment</i> , 2011, 40, 109-122.	2.8	29
95	Predictors of treatment outcome in adults with ADHD treated with OROS [®] methylphenidate. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2011, 35, 554-560.	4.8	31
96	Confirmatory Factor Analysis of Borderline Personality Disorder symptoms based on two different interviews: The Structured Clinical Interview for DSM-IV Axis I Disorder and the Revised Diagnostic Interview for Borderlines. <i>Psychiatry Research</i> , 2011, 190, 304-308.	3.3	17
97	Amphetamines for Attention Deficit Hyperactivity Disorder (ADHD) in adults. <i>The Cochrane Library</i> , 2011, , CD007813.	2.8	58
98	Training-induced neuroanatomical plasticity in ADHD: A tensor-based morphometric study. <i>Human Brain Mapping</i> , 2011, 32, 1741-1749.	3.6	43
99	Protocols of Dual Diagnosis Intervention in Schizophrenia. <i>Addictive Disorders and Their Treatment</i> , 2011, 10, 131-154.	0.5	11
100	Diferencias de género epidemiológicas y diagnósticas según eje I en pacientes con Patología Dual. <i>Revista De Psicología De La Salud</i> , 2011, 23, 165.	0.5	18
101	Fumar en las psicosis afectivas: revisión sobre el consumo de nicotina en el trastorno bipolar y esquizoafectivo. <i>Revista De Psicología De La Salud</i> , 2011, 23, 65.	0.5	6
102	Enhanced neural activity in frontal and cerebellar circuits after cognitive training in children with attention-deficit/hyperactivity disorder. <i>Human Brain Mapping</i> , 2010, 31, 1942-1950.	3.6	64
103	Attention deficit hyperactivity disorder in adults. <i>World Journal of Biological Psychiatry</i> , 2010, 11, 684-698.	2.6	113
104	Multicenter Analysis of the SLC6A3/DAT1 VNTR Haplotype in Persistent ADHD Suggests Differential Involvement of the Gene in Childhood and Persistent ADHD. <i>Neuropsychopharmacology</i> , 2010, 35, 656-664.	5.4	180
105	Efficacy of Psychostimulant Drugs for Cocaine Dependence. , 2010, , CD007380.		89
106	Comorbid Attention-Deficit/Hyperactivity Disorder in Borderline Patients Defines an Impulsive Subtype of Borderline Personality Disorder. <i>Journal of Personality Disorders</i> , 2010, 24, 812-822.	1.4	84
107	Safety and tolerability of flexible dosages of prolonged-release OROS methylphenidate in adults with attention-deficit/hyperactivity disorder. <i>Neuropsychiatric Disease and Treatment</i> , 2009, 5, 457.	2.2	19
108	OROS methylphenidate for the treatment of adults with attention-deficit/hyperactivity disorder. <i>Expert Review of Neurotherapeutics</i> , 2009, 9, 1121-1131.	2.8	7

#	ARTICLE	IF	CITATIONS
109	Case-Control Study of Six Genes Asymmetrically Expressed in the Two Cerebral Hemispheres: Association of BAIAP2 with Attention-Deficit/Hyperactivity Disorder. <i>Biological Psychiatry</i> , 2009, 66, 926-934.	1.3	59
110	Efficacy of Opiate Maintenance Therapy and Adjunctive Interventions for Opioid Dependence with Comorbid Cocaine Use Disorders: A Systematic Review and Meta-Analysis of Controlled Clinical Trials. <i>American Journal of Drug and Alcohol Abuse</i> , 2009, 35, 339-349.	2.1	50
111	A Randomized, Placebo-Controlled Trial of Three Fixed Dosages of Prolonged-Release OROS Methylphenidate in Adults with Attention-Deficit/Hyperactivity Disorder. <i>Biological Psychiatry</i> , 2008, 63, 981-989.	1.3	167
112	Effect of Switching Drug Formulations from Immediate-Release to Extended-Release OROS Methylphenidate. <i>CNS Drugs</i> , 2008, 22, 603-611.	5.9	47
113	Efficacy of central nervous system stimulant treatment for cocaine dependence: a systematic review and meta-analysis of randomized controlled clinical trials. <i>Addiction</i> , 2007, 102, 1871-1887.	3.3	65
114	Relationship between cocaine use and mental health problems in a sample of European cocaine powder or crack users. <i>World Psychiatry</i> , 2005, 4, 173-6.	10.4	21
115	Cocaine Use in Europe – A Multi-Centre Study. <i>European Addiction Research</i> , 2004, 10, 139-146.	2.4	50
116	A Double-Blind, Placebo-Controlled Study of Olanzapine in the Treatment of Alcohol-Dependence Disorder. <i>Alcoholism: Clinical and Experimental Research</i> , 2004, 28, 736-745.	2.4	54
117	A Double-Blind, Placebo-Controlled Study of Naltrexone in the Treatment of Alcohol-Dependence Disorder: Results from a Multicenter Clinical Trial. <i>Alcoholism: Clinical and Experimental Research</i> , 2002, 26, 1381-1387.	2.4	100
118	The apomorphine test: a biological marker for heroin dependence disorder?. <i>Addiction Biology</i> , 2002, 7, 421-426.	2.6	5
119	A Double-Blind, Placebo-Controlled Study of Naltrexone in the Treatment of Alcohol-Dependence Disorder: Results from a Multicenter Clinical Trial. <i>Alcoholism: Clinical and Experimental Research</i> , 2002, 26, 1381-1387.	2.4	2
120	Striatal Dopaminergic D ₂ Receptor Density Measured by [¹²³ I]Iodobenzamide SPECT in the Prediction of Treatment Outcome of Alcohol-Dependent Patients. <i>American Journal of Psychiatry</i> , 2000, 157, 127-129.	7.2	94
121	Cocaine Use Immediately Prior to Entry in an Inpatient Heroin Detoxification Unit as a Predictor of Discharges Against Medical Advice. <i>American Journal of Drug and Alcohol Abuse</i> , 1997, 23, 267-279.	2.1	56
122	The apomorphine test in heroin addicts. <i>Addiction</i> , 1995, 90, 831-835.	3.3	11
123	Reliability of the Beck Depression Inventory in opiate-dependent patients. <i>Journal of Substance Use</i> , 0, , 1-6.	0.7	2